Sign inJoin waitlistJoin the waitlist

Aditya Bardia

Program Director, Breast Medical Oncology · UCLA Health

Credentials: · · · · · · · ·

History

Breast Medical Oncology · UCLA Health
Present
Division of Hematology-Oncology · UCLA Health
Present
Geffen School of Medicine, University of California Los Angeles
Present

Johns Hopkins Hospital Sidney Kimmel Comprehensive Cancer Center
Until 2011
Mayo Clinic College of Medicine and Science
Until 2008
All India Institute of Medical Sciences
2003

Research

Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition
Science · 2013 · 2,006 citations
Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis
Cell · 2014 · 1,934 citations
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
New England Journal of Medicine · 2021 · First of 31 authors · 1,378 citations

LS
Laura Spring
66 papers · 12 as a fellow
SI
Steven Isakoff
44 papers
Hope Rugo
41 papers
LE
Leif Ellisen
40 papers
Beverly Moy
39 papers
SW
Seth Wander
35 papers · 6 as a fellow
Sara Tolaney
34 papers
Sara Hurvitz
32 papers
DJ
Dejan Juric
30 papers
Kevin Kalinsky
30 papers
Arielle Medford
26 papers · 16 as a fellow
JO
Joyce O'Shaughnessy
24 papers

Grants

Synergistic Combinatorial DNA Damage Response/Repair Inhibition and Sacituzumab Govitecan in Triple-Negative Breast Cancer
National Cancer Institute · R01
PI · $2.8M · Massachusetts General Hospital
2022–2026

Clinical trials

Fulvestrant + Neratinib In Breast Cancer
Principal investigator · Withdrawn · Phase 2
Massachusetts General Hospital
2023–2025
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Site PI · Recruiting · Phase 1
Stemline Therapeutics, Inc.
2024–2029
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Sub-investigator · Recruiting · Phase 1, Phase 2
Marengo Therapeutics, Inc.
2025–2028